Giving patients a chance is what drives us. We are committed to developing safe and effective therapies for those suffering of a wide range of fibrotic diseases.

Pliant is currently targeting fibrotic diseases in a variety of organs and conditions, including the lung (IPF), liver (primary sclerosing cholangitis, NASH and cirrhosis), kidney (renal fibrosis), skin (scleroderma) and the gastrointestinal tract (stricturing Crohn’s disease).